Cargando…
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia
Despite significant progress made in the overall cure rate, the prognosis for relapsed and refractory malignancies in children remains extremely poor. Hence, there is an urgent need for studies that enable the timely selection of appropriate agents for Phase I clinical studies. The Pediatric Oncolog...
Autores principales: | Hoeksema, Kimberley A, Jayanthan, Aarthi, Cooper, Todd, Gore, Lia, Trippett, Tanya, Boklan, Jessica, Arceci, Robert J, Narendran, Aru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176174/ https://www.ncbi.nlm.nih.gov/pubmed/21949608 http://dx.doi.org/10.2147/OTT.S21553 |
Ejemplares similares
-
Aurora Kinases as Druggable Targets in Pediatric Leukemia: Heterogeneity in Target Modulation Activities and Cytotoxicity by Diverse Novel Therapeutic Agents
por: Jayanthan, Aarthi, et al.
Publicado: (2014) -
Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition
por: Jayanthan, Aarthi, et al.
Publicado: (2011) -
Contribution of NIH funding to new drug approvals 2010–2016
por: Galkina Cleary, Ekaterina, et al.
Publicado: (2018) -
Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019) -
Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)